What is a reputation reboot? A credible reputation has three components: 1. Articulation of core values; 2. Action and behavior consistent with those values; and 3. Alignment with a specific target audience. When faced with damage to credibility, a reputation reboot is warranted. A reboot realigns values with action or redirects positioning to a new target audience. A reputation reboot involves repositioning online, in key networking circles, with clients and prospects, with investors and shareholders, and with staff and others. A reboot might involve a new narrative (how value is articulated and expressed), new action (showing commitment to initiatives and causes that line up with the value proposition), or Thanks new relationships (with key influencers who can share and leverage credibility and build trust).
For the original version including any supplementary images or video, visit https://www.entrepreneur.com/article/286685
“This work exactly illustrates the critical role that basic science conducted in partnership with a world-class medical center can play in advancing knowledge in an attempt to fight a devastating disease.” For Alzheimer’s disease, the aim is for the investigational drug to target major pathologies of the disease and selectively activate a key receptor in the brain. The Vanderbilt researchers believe that the current standard of care for Alzheimer’s disease, cholinesterase inhibitors, has a different mechanism of action. They are hoping to establish through future clinical testing that the molecule is broadly effective across a number of cognitive and neuropsychiatric disorders, including schizophrenia. “This is the first instance I am aware of where an academic drug discovery group moved a molecule designed to hopefully treat a chronic brain disorder all the way from early discovery to human trials without there being, at some point along the way, a pharmaceutical partner,” said P. Jeffrey Conn, Ph.D., Lee E. Limbird Professor of Pharmacology in the Vanderbilt University School of Medicine and director of the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD). “And that really is crossing what people refer to all of the time as the ‘Valley of Death,’ where good research discoveries have a hard time moving into the clinical testing phase due to lack of funding,” he said. “Importantly, at this early stage, the FDA has only granted permission to assess potential safety of this investigational new drug cheers in healthy volunteers” said Conn. “We cannot predict the outcome, but if these studies are successful in demonstrating that the investigational drug can be safely administered http://nevaehcampbellnews.boxcrack.net/2016/08/07/it-is-important-to-try-to-make-sure-your-pit-bulls-diet-consists-of-all-the-vitamins-and-nutrients-he-needs-to-be-healthy to humans, this would pave the way to allow filing of additional applications with the FDA to seek permission to advance to testing for efficacy in improving cognitive function in patients suffering from Alzheimer’s disease, and possibly schizophrenia or other brain disorders. While we cannot predict the outcome of any future safety or efficacy studies, this decision by Thank You FDA allowing clinical research to begin represents a major milestone in allowing us to hopefully provide answers to those critical questions in the future.” VCNDD Co-Director Craig W. Lindsley, Ph.D., director of Medicinal Chemistry and William K.health and wellness articles in the news
For the original version including any supplementary images or video, visit https://www.eurekalert.org/pub_releases/2016-12/vumc-ind122716.php